AstraZeneca’s Covid antibody drug was rejected by England’s cost regulator as it’s unlikely to work against most circulating virus strains and is not cost-effective for the struggling NHS https://t.co/Eh81hPZ3Fz— Bloomberg (@business) February 16, 2023
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


